Drug intelligence / Profile preview

adalimumab + metronidazole

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of adalimumab (a TNF-alpha inhibitor) and metronidazole (a nitroimidazole antibiotic). This combination has been studied specifically for preventing post-operative recurrence in high-risk Crohn's disease patients following intestinal resection. Adalimumab binds to TNF-alpha and blocks its interaction with surface TNF receptors, while metronidazole provides antimicrobial effects. Studies have shown this combination to be superior to thiopurines with metronidazole in preventing early disease recurrence.

Targets

TNFA (Tumor necrosis factor alpha (soluble))Neuraminidase

Beyond the preview

Go deeper on adalimumab + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + metronidazole.

Explore the full profile